2 most recent filings and news items mentioning CAMP. Updated every 60 seconds.
Offering|RegulatoryJul 27, 2026Neutral
Camp4 Therapeutics received Australian regulatory approval to begin a Phase 1/2 clinical trial of CMP-002 for SYNGAP1 disorder. This milestone enables a second private offering that could raise up to $50 million.
View filing at SEC.gov →
NewsJun 16, 2026Neutral
W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday
View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.